Ceftriaxone-induced immune hemolytic anemia as a life-threatening complication of antibiotic treatment of ‘chronic Lyme disease’

References

• Feder HM Jr, Johnson BJ, O’Connell S, Shapiro ED, Steere AC, Wormser GP, et al. A critical appraisal of “chronic lyme disease”. N Engl J Med. 2007;357:1422–30.10.1056/NEJMra072023
   PubMed Web of Science ®Google Scholar
• Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of lyme disease. N Engl J Med. 2001;345:85–92.10.1056/NEJM200107123450202
   PubMed Web of Science ®Google Scholar
• Kaplan RF, Trevino RP, Johnson GM, Levy L, Dornbush R, Hu LT, et al. Cognitive dysfunction in post-treatment Lyme disease: do additional antibiotics help? Neurology. 2003;60:1916–22.10.1212/01.WNL.0000068030.26992.25
   PubMed Web of Science ®Google Scholar
• Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70:992–1003.10.1212/01.WNL.0000284604.61160.2d
   PubMed Web of Science ®Google Scholar
• Halperin JJ. Prolonged Lyme disease treatment: enough is enough. Neurology. 2008;70:986–7.10.1212/01.WNL.0000291407.40667.69
   PubMed Web of Science ®Google Scholar
• Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, et al. Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology. 2003;60:1923–30.10.1212/01.WNL.0000071227.23769.9E
   PubMed Web of Science ®Google Scholar
• Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69:258–71.10.1002/(ISSN)1096-8652
   PubMed Web of Science ®Google Scholar
• Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24:143–50.10.1016/j.blre.2010.06.004
   PubMed Web of Science ®Google Scholar
• Garratty G. Drug-induced immune hemolytic anemia. Hematol Am Soc Hematol Educ Program. 2009;73–9.10.1182/asheducation-2009.1.73
   PubMedGoogle Scholar
• Garbe E, Andersohn F, Bronder E, Klimpel A, Thomae M, Schrezenmeier H, et al. Drug induced immune haemolytic anaemia in the Berlin case-control surveillance study. Br J Haematol. 2011;154:644–53.10.1111/j.1365-2141.2011.08784.x
   PubMed Web of Science ®Google Scholar
• Arndt PA, Leger RM, Garratty G. Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia. Transfusion. 2012;52:602–12.10.1111/trf.2012.52.issue-3
   PubMed Web of Science ®Google Scholar
• Johnson ST, Fueger JT, Gottschall JL. One center’s experience: the serology and drugs associated with drug-induced immune hemolytic anemia–a new paradigm. Transfusion. 2007;47:697–702.10.1111/trf.2007.47.issue-4
   PubMed Web of Science ®Google Scholar
• Steere AC. Lyme disease. N Engl J Med. 2001;345:115–25.10.1056/NEJM200107123450207
   PubMed Web of Science ®Google Scholar
• Belkhir L, Costers M, Delaere B, De Loof G, De Munter P, Frippiat F, et al. Lyme-borreliose (infectie met Borrelia). FOD Volksgezondheid – BAPCOC; 2015.
   Google Scholar
• Luger SW, Paparone P, Wormser GP, Nadelman RB, Grunwaldt E, Gomez G, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother. 1995;39:661–7.10.1128/AAC.39.3.661
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance: Lyme disease (revised 9/96). MMWR Morb Mortal Wkly Rep. 1997;46:1–51.
   PubMedGoogle Scholar
• Treatment of Lyme disease. Med Lett Drug Ther. 2005;47:41–3.
   PubMed Web of Science ®Google Scholar
• Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the infectious diseases society of America. Clin Infect Dis. 2006;43:1089–134.10.1086/508667
   PubMed Web of Science ®Google Scholar
• Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM. Death from inappropriate therapy for lyme disease. Clin Infect Dis. 2000;31:1107–9.10.1086/cid.2000.31.issue-4
   PubMed Web of Science ®Google Scholar
• Holzbauer SM, Kemperman MM, Lynfield R. Death due to community‐associated Clostridium difficile in a woman receiving prolonged antibiotic therapy for suspected Lyme disease. Clin Infect Dis. 2010;51:369–70.10.1086/652977
   PubMed Web of Science ®Google Scholar
• Ettestad PJ, Campbell GL, Welbel SF, Genese CA, Spitalny KC, Marchetti CM, et al. Biliary complications in the treatment of unsubstantiated lyme disease. J Infect Dis. 1995;171:356–61.10.1093/infdis/171.2.356
   PubMed Web of Science ®Google Scholar
• Snapper I, Marks D, Schwartz L, Hollander L. Hemolytic anemia secondary to mesantoin. Ann Intern Med. 1953;39:619–23.
   PubMed Web of Science ®Google Scholar
• Garratty G, Arndt PA. An update on drug-induced immune hemolytic anemia. Immunohematology. 2007;23:105–19.
   PubMedGoogle Scholar
• Arndt PA, Leger RM, Garratty G. Serology of antibodies to second- and third-generation cephalosporins associated with immune hemolytic anemia and/or positive direct antiglobulin tests. Transfusion. 1999;39:1239–46.10.1046/j.1537-2995.1999.39111239.x
   PubMed Web of Science ®Google Scholar
• Salama A, Mueller-Eckhardt C. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N Engl J Med. 1985;313:469–74.10.1056/NEJM198508223130803
   PubMed Web of Science ®Google Scholar
• Salama A. Drug-induced immune hemolytic anemia. Expert Opin Drug Saf. 2009;8:73–9.10.1517/14740330802577351
   PubMed Web of Science ®Google Scholar
• Seltsam A, Salama A. Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature. Intensive Care Med. 2000;26:1390–4.10.1007/s001340000598
   PubMed Web of Science ®Google Scholar
• Arndt PA, Garratty G. Cross-reactivity of cefotetan and ceftriaxone antibodies, associated with hemolytic anemia, with other cephalosporins and penicillin. Am J Clin Pathol. 2002;118:256–62.10.1309/JFJE-VUKN-221T-G6EV
   PubMed Web of Science ®Google Scholar